Paul Dyer, Ph.D.

Thought provoking 🧠 and insightful 💡 blog from Brandon Wickins on lab screening vs. POCT 👉 https://lnkd.in/eNCTkjCJ Do you need UKAS accredited laboratory screening? AttoSure is here to help. Message us for more information. #drugtesting #drugscreening #safetyatwork #laboratoryscreening

5

In this blog Isogenica delves into VHH-based therapies. It explains how its synthetic, humanised single chain VHH antibodies are a solution to the challenges of engineering next-generation cell therapies. https://ow.ly/hK0550SVIBa

2

Come to join us to learn all the tips and tricks to optimise your spectral workflow!

5

The UK Biobank's extensive data on protein measurements and whole exome sequences is a treasure trove for researchers. This recent study leveraged this resource to uncover potential links between plasma proteins and cancer risk. After analyzing 1463 proteins and their association with 19 different cancers, they've identified 618 potential protein-cancer associations. Notably, 107 of these associations were detectable for cases diagnosed more than seven years post blood draw. This long-term analysis, coupled with genetic approaches like cis-pQTL and exome-wide protein genetic scores, has revealed promising insights. For instance, proteins such as CD74 and TNFRSF1B with non-Hodgkin lymphoma, ADAM8 with leukemia, and SFTPA2 with lung cancer, show potential roles in cancer development. These findings not only advance our understanding of cancer but also highlight the predictive potential of blood proteins, opening new avenues for early detection and prevention strategies p/b University of Oxford, Queen's University Belfast, Keren Papier, Kezia Gaitskell, Trishna Desai, Chibuzor Ogamba, Mahboubeh Parsaeian, Gillian Reeves, Karl Smith Byrne #CancerResearch #Multiomics #UKBiobank https://lnkd.in/gVBA58bx

19

Have you seen our latest piece in Drug Discovery World? Follow the link below to read the piece by our Senior Bioassay Scientist Dr Gareth Edwards. #Neuroinflammation #Neuroscience #InVitroModels

12

Looking for support to develop a robust Target Product Profile (TPP) for your #AdvancedTherapy? ➡️ https://ow.ly/2Ov250TcBl4 Take a look at our guide to developing a #TPP ☝️ #CellTherapy #GeneTherapy #ATMP #AdvancedTherapies

13

The application deadline is fast approaching for this course that will introduce you to the technology, data analysis, tools and resources used in RNA sequencing:  https://lnkd.in/ebPuYEYa Make sure you’ve submitted your application by 24 November. This virtual course will cover: - High throughput sequencing technologies for RNA-Seq  -Basics of experimental design -RNA-seq file formats -RNA-seq bioinformatics workflow steps following sequence generation -Methods for transcriptomics; QC, mapping, and visualisation tools -Data resources to assist in the functional analysis and interpretation of transcriptomic data -Introduction to de novo approaches (options in the absence of a reference) -Fundamentals of pipeline implementation (with Nextflow) for bulk RNA-seq analysis Data resources covered: -Expression Atlas -g:Profiler -Sequencing repositories: ENA, GEO, SRA We are also able to offer a limited number of registration fee waivers for this course. If you receive a waiver, your registration fee will be reimbursed after you have completed the course. #RNA #RNAseq #datascience #commandline #bioionformatics #sciencelearning #sciencetraining #EMBL #EMBLEBI

56

Our scientists understand the importance of keeping up to date with the literature so they are aware of the latest developments. Mark Stewart (Group Leader, Medicinal Chemistry) has written our latest "Medicinal Chemistry in Review" blog which describes the discovery of selective, potent, and mutant-active MET inhibitors with intracranial efficacy, by a team at Pfizer. https://lnkd.in/eYa4JAMB Take a look. We hope you enjoy reading it. #DrugDiscovery #MedicinalChemistry

31

1 Comment

To continue the awareness of World Antimicrobial Resistance Week 2024, in a series of upcoming articles the Mewburn AMR team will explore a number of key issues and unique solutions in the field introduced below, and discuss how IP and incentives can be used to support researchers tackling AMR. In this blog, Emily Lythell, PhD explores how AI and phage therapy are combating antimicrobial resistance, discovering new antibiotics, and improving diagnostics - https://hubs.la/Q02Z2btq0 Read our other AMR awareness week post - https://hubs.la/Q02Z28w60 #MewburnLifeSciences #AntimicrobialResistance #AMR #AntibioticResistance #OneHealth #IP #Pharma #ArtificalIntelligence #MewburnMicrobiome

23

1 Comment

Spin-out Chromatwist has won a prestigious Innovate UK Smart grant to co-fund a £0.5 million project that will take its novel dyes to the next level, enhancing their brightness and staining indices to make cells and cellular structures stand out more clearly during bio-imaging. The funding from Innovate UK, the UK’s innovation agency covers 70% of the project costs. It will also allow ChromaTwist, which is currently raising funds, to push on with technical development and prepare for scale-up and commercial launch, to continue its collaboration with The Babraham Institute in Cambridge, UK. ChromaTwist was founded as a spin-out following the discovery of a new class of fluorescent materials at the University of Birmingham, and is developing over 70 innovative patented UV excitable dyes that emit blue through to red (and potentially into the Near IR). The dyes promise to improve understanding of complex biological processes, leading to more precise diagnostics and new therapies. The company has already developed the dye chemistry to enable conjugation to antibodies and demonstrated exceptional utility and promise in flow cytometry and multiphoton microscopy. Several global flow cytometry players have tested the ChromaTwist conjugates and reproduced the ChromaTwist data. They are now eagerly waiting for the next iteration of ChromaTwist dyes, which have the potential to set new standards in the field. Professor Jon Preece, FRSC, CEO of ChromaTwist, said: “We can take the development of our UV excitable dyes to the next level, and forge a deeper collaboration with the world-renowned flow cytometry facility at the Babraham Institute.” Dr Rachael Walker, Head of Flow Cytometry at the Babraham Institute, added, “I am delighted to continue our productive partnership. Our diverse group of users will be able to test these dyes across a range of biological sample types.” ChromaTwist has already raised funding from existing angel investors, Angel Groups, and private equity investment, and was identified as ‘one to watch’ in the Nature Research 2020 Spinoff Prize.  For commercial information and investment please contact Jon Preece on LinkedIn or via the contact form on the ChromaTwist website: https://lnkd.in/exASY5cT #Innovation #BioImaging #FlowCytometry #ChromaTwist #UVExcitableDyes #ScientificResearch #Diagnostics #InnovateUK #BiomedicalResearch #FluorescentDyes #CellBiology #TherapeuticDevelopment Royal Society of Chemistry | International Society for Advancement of Cytometry | Royal Microscopical Society | Euro-BioImaging

176

18 Comments

*Molecules of the Month - July Edition* This month, our MotM focuses on Target Protein Degradation and some of the medicinal chemistry approaches that are applied within this area of drug discovery. Read on to find out how LCC's proprietary linkers, virtual libraries and parallel synthesis capabilities can help accelerate you drug discovery efforts. 👇 #TargetProteinDegradation #Linkers #VirtualLibraries #DrugDiscovery

28

🔬 ProteoGenix and Cizzle Biotechnology Collaboration Advances Early Lung Cancer Detection Innovative Antibody Development We're excited to announce that ProteoGenix and Cizzle Biotechnology plc have successfully developed new antibodies targeting the CIZ1B biomarker, associated with early-stage lung cancer. This collaboration promises to enhance early detection methods, addressing critical diagnostic needs. Key Points: 🧬 Enhanced Detection: New antibodies improve early lung cancer diagnostics. 🤝 Collaborative Success: Combines ProteoGenix's antibody expertise with Cizzle's diagnostic focus. 🌟 Future Impact: Aims for rapid commercialization and improved patient outcomes. For more details, read the full article on our website: https://buff.ly/4bzeu1w #LungCancer #EarlyDetection #Biotechnology #CizzleBio #HealthcareInnovation

3

1 Comment

Day 2 Wellcome Genome Campus #SCB24. So interesting to see integration of spatial datasets in single cell biology applications and how this is increasing our understanding of cellular interactions and tissue organisation. If you haven’t had a chance to discuss MERFISH spatial technology with me 🐠 please feel free to find me. #spatailbiology #singlecell #spatialtranscriptomics

58

2 Comments

What are the key differences between recombinant, monoclonal and polyclonal antibodies? 🔬 Today, we share an introductory guide on antibody types for those looking to orientate themselves in this field, or get a quick refresh! We also delve into the importance of antibody validation, and how antibody use has changed over time. Read more here ⬇️ https://lnkd.in/eM2refBb

9

Introducing Hycult Biotech , an ISO-13485 certified manufacturer of research reagents. Specialising in antibodies and immunoassays for innate immunity research since 1994, Hycult Biotech delivers reliable tools for complement, neutrophil proteins, toll-like receptors, scavenger receptors, and more. Want to find out more? Head over to our website or send us a message. #Biotechnology #Bioscience #Immunology

27

❗ RSC Medicinal Chemistry is pleased to announce that its themed collection on Induced-Proximity Pharmacology is now open to submissions ❗ This themed collection, guest edited by Lyn Jones, Ingo Hartung and Lindsey James, will highlight the latest advances in induced-proximity pharmacology, covering the following topics:      • Medicinal chemistry design and optimization of molecular glue and      heterobifunctional degraders (e.g. PROTACs)      • Medicinal chemistry of induced-proximity pharmacology beyond      targeted protein degradation      • Structure-activity/property/toxicity relationships that provide general      learning for medicinal chemists working in the field of induced-proximity      • Development of novel protein ligands (including peptides or      oligonucleotides) to enable the design of molecules that induce      biomolecule proximity      • Design and development of RNA modulators using induced-proximity      approaches      • Application of in silico empowered or miniaturized/automated      approaches to streamline the identification or optimization of proximity      inducing drug candidates      • Medicinal chemistry of biotherapeutics that possess an induced      proximity mode of action      • Elucidation of molecular mechanisms of induced-proximity      pharmacology using chemical techniques that aid drug development The deadline to submit is 23rd October 2024 🔔 Find out more about the collection and how to submit, here: https://lnkd.in/eGAzYTdk #OpenCall #RSCMedChem #RSCChemBio

43

Great #STEM for Britain opportunity in London 🇬🇧 for those at #earlycareer, do consider ✍️ They are interested to have scientists, engineers, technologists and mathematicians for the opportunity to exhibit in one of the five areas: ❤️ #Biological and #Biomedical #Sciences ⚗️ #Chemistry ⚙️Engineering 🧮 Mathematical Sciences 🚀 Physics 🚨I like the definition of early career: early part of their careers- #MSc, #PhD, #PostDocs, #ResearchAssistants or #Fellows, recently-appointed #lecturers, part-time and “mature” students and their equivalents in national, public sector and industrial laboratories, or companies. The event is not appropriate for undergraduate students. We welcome returners, and those starting a second career – age is unimportant.

21

Exciting News! 🌟 Revivocell receives funding from STFC for our NANOSTACKS CNS modeling tech! Shaping the future of brain modeling!🧠💡 Our AI-driven platform predicts neurotoxicity in drug candidates early on, transforming neuroscience research and drug discovery. #Revivocell #NANOSTACKS #AI #Neuroscience"

3

Today, 25th April, marks the anniversary of the completion of the human genome project in 2003 and the discovery of the double helix in 1953. As we celebrate DNA Day, our recently appointed CEO, Simon Davis, reflects on how much progress has been made in genomics since then and how that science has enabled Informed Genomics to help clinicians diagnose cancers earlier, personalise treatments and improve patient outcomes. Read the Q&A session here! https://bit.ly/4ba2sMj #DnaDay #InformedGenomics #Human #Genome #DNA

44

2 Comments